SAN DIEGO, July 26, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether DexCom, Inc. (NASDAQ: DXCM) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws. What if I purchased DexCom securities? If you purchased securities and suffered losses on you ...

DexCom (NASDAQ:DXCM) stock is falling on Friday after the company released its earnings report for Q2 2024.DexCom starts its earnings report with adjusted earnings per share of 43 cents. That’s better than Wall Street’s estimate of 39 cents per share. It’s also an improvement over its adjusted EPS of 34 cents in the same period of the year prior.However, the company’s revenue of $1 billion failed to impress. It doesn’t stack up to analysts’ estimate of $1.04 billion. Even if its a 15% increase year-over-yea ...

U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Friday.Shares of DexCom, Inc. DXCM fell sharply during Friday's pre-market trading after the company reported worse-than-expected second-quarter revenue results and issued weak FY24 revenue guidance.DexCom reported quarterly earnings of 43 cents per share, which beat the analyst consensus estimate of 39 cents. Quarterly sales came in at $1.004 billion which missed the analyst consensus estimate of $1.036 billion.D ...

martin-dm/E+ via Getty Images Investment Thesis DexCom (NASDAQ:DXCM) reported one of the most disappointing Q2 earnings reports of this earnings season, with the company missing its estimates by 4% on the top end while managing to edge past the market's EPS expectations set for DexCom. This was a rare and shocking miss for the San Diego, CA-headquartered company, which reported a puzzling slowdown in sales in the U.S. market, still faring better than its sales in its international markets outside the U.S., ...

Key TakeawaysShares in Dexcom plunged in extended trading Thursday after the medical devices company posted second quarter results that came in below Wall Street expectations and slashed its annual revenue forecast.Dexcom shares look set to break down from a symmetrical triangle, a chart pattern that often precedes a trending move in the direction of the breakout.The Dexcom share price could attract buying interest at key chart levels including $70, $52, $37, and $24.On the four occasions the relative stren ...

DexCom, Inc. (NASDAQ:DXCM) Q2 2024 Earnings Conference Call July 25, 2024 4:30 PM ET Corporate Participants Sean Christensen - Vice President of Finance, and Investor Relations Kevin Sayer - Chairman, President, and Chief Executive Officer Jereme Sylvain - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Jeff Johnson - Baird Magaret Andrew - William Blair Travis Steed - Bank of America Matt Taylor - Jefferies Danielle Antalffy - UBS Joanne Wuensch - ...

DexCom (DXCM) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.34 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.26%. A quarter ago, it was expected that this medical device company would post earnings of $0.27 per share when it actually produced earnings of $0.32, delivering a surprise of 18.52%.Over the last four quarters, the co ...

Key TakeawaysShares of Dexcom tumbled in extended trading Thursday after the company reported second-quarter earnings that missed estimates and slashed its full-year revenue guidance.The maker of glucose monitors said it now expects organic revenue growth of 11% to 13%, down from its projection in April of 17% to 21%.The second quarter "did not meet our high standards," CEO Kevin Sayer said. Shares of Dexcom (DXCM) tumbled over 40% in extended trading Thursday after the company reported second-quarter earni ...

Table of Contents DEXCOM, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51222 (Exact name of registrant as specified in its charter) Delaware 33-0857544 (State or other jurisdictio ...

Core Insights - Dexcom's shares fell over 34% in after-hours trading following disappointing Q2 revenue and weak guidance [1] - The company reported adjusted earnings per share of 43 cents, exceeding the expected 39 cents, but revenue of $1 billion fell short of the $1.04 billion forecast [1] - Revenue increased by 15% year-over-year from $871.3 million, with net income rising to $143.5 million from $115.9 million [1] Financial Performance - Q2 adjusted earnings per share: 43 cents vs. 39 cents expected [1] - Q2 revenue: $1 billion vs. $1.04 billion expected [1] - Year-over-year revenue growth: 15% from $871.3 million [1] - Net income for Q2: $143.5 million, up from $115.9 million [1] Future Guidance - Q3 revenue expectation: between $975 million to $1 billion [1] - Updated full fiscal year revenue guidance: between $4 billion and $4.05 billion, down from previous guidance of $4.20 billion to $4.35 billion [1] Strategic Initiatives - CEO Kevin Sayer acknowledged that execution did not meet high standards despite advancing key strategic initiatives [2] - The company sees a unique opportunity to serve more customers globally with its differentiated product portfolio [2] - Actions are being taken to improve execution and position the company for long-term growth [2]